Jamie Clark
Stock Analyst at Rothschild & Co
(2.49)
# 2,418
Out of 5,050 analysts
9
Total ratings
71.43%
Success rate
9.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jamie Clark
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WST West Pharmaceutical Services | Initiates: Buy | $311 | $271.04 | +14.74% | 1 | Sep 15, 2025 | |
| MEDP Medpace Holdings | Downgrades: Neutral | $342 → $474 | $589.15 | -19.55% | 1 | Sep 3, 2025 | |
| ICLR ICON Public Limited Company | Upgrades: Buy | $184 → $236 | $159.14 | +48.30% | 1 | Sep 3, 2025 | |
| CRL Charles River Laboratories International | Upgrades: Buy | $188 → $182 | $168.05 | +8.30% | 3 | May 23, 2025 | |
| LH Labcorp Holdings | Initiates: Buy | $276 | $252.72 | +9.21% | 1 | Apr 2, 2025 | |
| DGX Quest Diagnostics | Initiates: Buy | $195 | $179.50 | +8.64% | 1 | Apr 2, 2025 | |
| IQV IQVIA Holdings | Initiates: Buy | $276 | $210.46 | +31.14% | 1 | Oct 14, 2024 |
West Pharmaceutical Services
Sep 15, 2025
Initiates: Buy
Price Target: $311
Current: $271.04
Upside: +14.74%
Medpace Holdings
Sep 3, 2025
Downgrades: Neutral
Price Target: $342 → $474
Current: $589.15
Upside: -19.55%
ICON Public Limited Company
Sep 3, 2025
Upgrades: Buy
Price Target: $184 → $236
Current: $159.14
Upside: +48.30%
Charles River Laboratories International
May 23, 2025
Upgrades: Buy
Price Target: $188 → $182
Current: $168.05
Upside: +8.30%
Labcorp Holdings
Apr 2, 2025
Initiates: Buy
Price Target: $276
Current: $252.72
Upside: +9.21%
Quest Diagnostics
Apr 2, 2025
Initiates: Buy
Price Target: $195
Current: $179.50
Upside: +8.64%
IQVIA Holdings
Oct 14, 2024
Initiates: Buy
Price Target: $276
Current: $210.46
Upside: +31.14%